The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination ...

FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid ...

Following its acquisition by Supernus Pharmaceuticals, Sage Therapeutics has let go of all of its remaining workforce, which ...

Leerink Partners analyst Mani Foroohar maintained a Sell rating on Moderna on June 30. The company’s shares closed yesterday at $28.69. Foroohar covers the Healthcare sector, focusing on stocks such ...

The global Vaccines Market is estimated to be valued at USD 54.50 billion in 2025 and is projected to reach USD 111.3 billion by 2035, registering a compound annual growth rate (CAGR) of 7.4% over the ...

The US Advisory Committee on Immunization Practices voted in June to stop recommending certain kinds of flu vaccines, a ...

The African Pharmaceutical Market is projected to grow at an impressive CAGR of 6-8% by 2029, driven by a booming population, ...

Cambodia's health ministry today announced another human H5N1 avian flu case of the year, involving a 5-year-old boy from ...

Vaccine supply shortage comes at a bad time, as African countries make headway with their outbreaks and have seen good uptake ...